Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amakem Therapeutics
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Bristol-Myers Squibb sold its HIV pipeline to Viiv for $2.9 billion; AstraZeneca acquired a potential Imbruvica competitor by getting a controlling stake in Acerta; biopharma financing was up significantly thanks to a $7.2 billion ADS/debt offering by Teva Pharmaceutical.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced November-December 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
- Other Names / Subsidiaries
- Amakem NV